203 related articles for article (PubMed ID: 24587105)
1. Use of synthetic isoprenoids to target protein prenylation and Rho GTPases in breast cancer invasion.
Chen M; Knifley T; Subramanian T; Spielmann HP; O'Connor KL
PLoS One; 2014; 9(2):e89892. PubMed ID: 24587105
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho.
Kusama T; Mukai M; Tatsuta M; Nakamura H; Inoue M
Int J Oncol; 2006 Jul; 29(1):217-23. PubMed ID: 16773203
[TBL] [Abstract][Full Text] [Related]
3. "Smart" Nanoparticles Enhance the Cytoplasmic Delivery of Anti-RhoC Silencing RNA and Inhibit the Migration and Invasion of Aggressive Breast Cancer Cells.
Kaushal N; Durmaz YY; Bao L; Merajver SD; ElSayed ME
Mol Pharm; 2015 Jul; 12(7):2406-17. PubMed ID: 26020100
[TBL] [Abstract][Full Text] [Related]
4. Using inhibitors of prenylation to block localization and transforming activity.
Berzat AC; Brady DC; Fiordalisi JJ; Cox AD
Methods Enzymol; 2006; 407():575-97. PubMed ID: 16757354
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion.
Bourguignon LY; Wong G; Earle C; Krueger K; Spevak CC
J Biol Chem; 2010 Nov; 285(47):36721-35. PubMed ID: 20843787
[TBL] [Abstract][Full Text] [Related]
6. Rho isoform-specific interaction with IQGAP1 promotes breast cancer cell proliferation and migration.
Casteel DE; Turner S; Schwappacher R; Rangaswami H; Su-Yuo J; Zhuang S; Boss GR; Pilz RB
J Biol Chem; 2012 Nov; 287(45):38367-78. PubMed ID: 22992742
[TBL] [Abstract][Full Text] [Related]
7. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo.
Pillé JY; Denoyelle C; Varet J; Bertrand JR; Soria J; Opolon P; Lu H; Pritchard LL; Vannier JP; Malvy C; Soria C; Li H
Mol Ther; 2005 Feb; 11(2):267-74. PubMed ID: 15668138
[TBL] [Abstract][Full Text] [Related]
8. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling.
Zhong WB; Liang YC; Wang CY; Chang TC; Lee WS
Endocr Relat Cancer; 2005 Sep; 12(3):615-29. PubMed ID: 16172195
[TBL] [Abstract][Full Text] [Related]
9. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.
Fiordalisi JJ; Keller PJ; Cox AD
Cancer Res; 2006 Mar; 66(6):3153-61. PubMed ID: 16540666
[TBL] [Abstract][Full Text] [Related]
10. Novel farnesol and geranylgeraniol analogues: A potential new class of anticancer agents directed against protein prenylation.
Gibbs BS; Zahn TJ; Mu Y; Sebolt-Leopold JS; Gibbs RA
J Med Chem; 1999 Sep; 42(19):3800-8. PubMed ID: 10508429
[TBL] [Abstract][Full Text] [Related]
11. A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells.
Wang L; Yang L; Luo Y; Zheng Y
J Biol Chem; 2003 Nov; 278(45):44617-25. PubMed ID: 12939257
[TBL] [Abstract][Full Text] [Related]
12. Myosin-interacting guanine exchange factor (MyoGEF) regulates the invasion activity of MDA-MB-231 breast cancer cells through activation of RhoA and RhoC.
Wu D; Asiedu M; Wei Q
Oncogene; 2009 Jun; 28(22):2219-30. PubMed ID: 19421144
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers.
Wu M; Wu ZF; Rosenthal DT; Rhee EM; Merajver SD
Cancer; 2010 Jun; 116(11 Suppl):2768-82. PubMed ID: 20503409
[TBL] [Abstract][Full Text] [Related]
14. Farnesyl transferase inhibitor treatment of breast cancer cells leads to altered RhoA and RhoC GTPase activity and induces a dormant phenotype.
Chatterjee M; van Golen KL
Int J Cancer; 2011 Jul; 129(1):61-9. PubMed ID: 20824700
[TBL] [Abstract][Full Text] [Related]
15. Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification.
Roberts PJ; Mitin N; Keller PJ; Chenette EJ; Madigan JP; Currin RO; Cox AD; Wilson O; Kirschmeier P; Der CJ
J Biol Chem; 2008 Sep; 283(37):25150-25163. PubMed ID: 18614539
[TBL] [Abstract][Full Text] [Related]
16. LPA, HGF, and EGF utilize distinct combinations of signaling pathways to promote migration and invasion of MDA-MB-231 breast carcinoma cells.
Harrison SM; Knifley T; Chen M; O'Connor KL
BMC Cancer; 2013 Oct; 13():501. PubMed ID: 24160245
[TBL] [Abstract][Full Text] [Related]
17. The MLK-related kinase (MRK) is a novel RhoC effector that mediates lysophosphatidic acid (LPA)-stimulated tumor cell invasion.
Korkina O; Dong Z; Marullo A; Warshaw G; Symons M; Ruggieri R
J Biol Chem; 2013 Feb; 288(8):5364-73. PubMed ID: 23319595
[TBL] [Abstract][Full Text] [Related]
18. Impaired geranylgeranyltransferase-I regulation reduces membrane-associated Rho protein levels in aged mouse brain.
Afshordel S; Wood WG; Igbavboa U; Muller WE; Eckert GP
J Neurochem; 2014 May; 129(4):732-42. PubMed ID: 24428713
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
20. Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases.
Michaelson D; Ali W; Chiu VK; Bergo M; Silletti J; Wright L; Young SG; Philips M
Mol Biol Cell; 2005 Apr; 16(4):1606-16. PubMed ID: 15659645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
